Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination immunization regimen consisting of three separate vaccines administered together or as a co-formulation for pediatric use: - sIPV (inactivated poliovirus vaccine, Salk strain): provides immunity against poliomyelitis by inducing antibodies to all three types of poliovirus. - DTaP (diphtheria, tetanus toxoid, and acellular pertussis): protects against diphtheria by neutralizing the diphtheria toxin; against tetanus by neutralizing the tetanospasmin toxin; and against pertussis through immune response to *Bordetella pertussis* antigens. - HepA (hepatitis A vaccine): induces immunity to hepatitis A virus infection via inactivated viral antigen. These vaccines are commonly administered as part of routine childhood immunization schedules. The mechanism of action for each component is induction of active immunity via antigen presentation leading to antibody production specific for each pathogen or toxin. These vaccines are typically developed and manufactured by major global pharmaceutical companies specializing in pediatric vaccines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sIPV + DTaP + HepA.